*Supplementary Material for*

[FeIIICl(TMPPH2)][FeIIICl4]2: A Stand-alone Molecular Nanomedicine that Induces High Cytotoxicity by Ferroptosis

Xiao Wang,1,# Jia-Hao Feng,2,# Chun-Mei Zeng,1 Ze-Sheng Zhang,1 Feng-Lin Cao,1 Wen-Hua Zhang,1,\*  
Jin-Xiang Chen,2,\* Yiming Mao,3,\* and David J. Young4

|  |
| --- |
|  |

1 College of Chemistry, Chemical Engineering, and Materials Science, Soochow University, Suzhou 215123, China

2 NMPA Key Laboratory for Research and Evaluation of Drug Metabolism, Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China

3 Department of Thoracic Surgery, Suzhou Kowloon Hospital, Shanghai Jiaotong University School of Medicine, Suzhou 215021, China.

4 Glasgow College UESTC, University of Electronic Science and Technology of China, Chengdu 611731, China

# These authors contributed equally to this work

**\*** Correspondence: whzhang@suda.edu.cn (W.-H.Z.); jxchen@smu.edu.cn (J.-X.C.); mym19850126@163.com (Y.M.)

**Table of Contents**

[**Figure S1.** The molecular packing diagram of **Fe-TMPP** looking along the crystallographic *a* direction showing the H-bonding among the molecules. 3](#_Toc165194709)

[**Figure S2.** A comparison of the FT-IR spectra of H2TMPP and **Fe-TMPP**. 4](#_Toc165194710)

[**Figure S3.** Tyndall effect of **Fe-TMPP** in the aqueous solution. 5](#_Toc165194711)

[**Figure S4.** The EDS elemental ratios of the as-synthesized **Fe-TMPP** (a) and that from the lyophilized sample (b; 10 mg in 10 mL of water, sonicated and kept for 24 h), showing no obvious change of the chemical composition. 6](#_Toc165194712)

[**Figure S5.** The DLS results of three **Fe-TMPP** aqueous solutions. 7](#_Toc165194713)

[**Figure S6.** The zeta potential results of **Fe-TMPP** in aqueous solution. 8](#_Toc165194714)

[**Figure S7.** Pictures of **Fe-TMPP** dispersed in aqueous solution for 0−3 days. 9](#_Toc165194715)

[**Figure S8.** UV-Vis absorption spectra of **Fe-TMPP** dispersed in aqueous solution for 0−3 days. 10](#_Toc165194716)

[**Figure S9.** The DLS results of **Fe-TMPP** in PBS (0.1x) for 0 (a), 12 (b), and 24 hours (c). 11](#_Toc165194717)

[**Figure S10.** The zeta potential results of **Fe-TMPP** in PBS (0.1x) for 0 (a), 12 (b) and 24 hours (c). 12](#_Toc165194718)

[**Figure S11.** A comparison of the PXRD spectra of **Fe-TMPP** and its lyophilized samples after sonication and kept in different amounts of water for 24 h. 13](#_Toc165194719)

[**Figure S12.** TEM image of **TMPP-F127**. 14](#_Toc165194720)

[**Figure S13.** UV-Vis absorption spectra of DPBF (a) and its dispersion in **TMPP-F127** (b) and **Fe-TMPP** (c) aqueous solution with different illumination times. The changes of absorption intensity at 416 nm of DPBF as a function of irradiation time when incubated with **TMPP-F127** and **Fe-TMPP** using blank DPBF as a control (d). 15](#_Toc165194721)

[**Figure S14.** A comparison of fluorescence intensity of DCF when treated with **TMPP-F127**, **Fe-TMPP**, and PBS control. 16](#_Toc165194722)

[**Figure S15.** A comparison of the HCT-116 (a), HuH-7 (b), and BXPC3 (c) cell viabilities when treated with gradient concentrations of **TMPP-F127** and **Fe-TMPP**. The DLD-1, PC3, and AGS cells viabilities when treated with gradient concentrations of **Fe-TMPP** (d). 17](#_Toc165194723)


[**Table S1.** Detailed cell development and drug incubation conditions. 18](#_Toc165194724)

****


**Figure S1.** The molecular packing diagram of **Fe-TMPP** looking along the crystallographic *a* direction showing the H-bonding among the molecules.

****


**Figure S2.** A comparison of the FT-IR spectra of H2TMPP and **Fe-TMPP**.




**Figure S3.** Tyndall effect of **Fe-TMPP** in the aqueous solution.



**Figure S4.** The EDS elemental ratios of the as-synthesized **Fe-TMPP** (a) and that from the lyophilized sample (b; 10 mg in 10 mL of water, sonicated and kept for 24 h), showing no obvious change of the chemical composition.

****

**Figure S5.** The DLS results of three **Fe-TMPP** aqueous solutions.

****

**Figure S6.** The zeta potential results of **Fe-TMPP** in aqueous solution.



**Figure S7.** Pictures of **Fe-TMPP** dispersed in aqueous solution for 0−3 days.




**Figure S8.** UV-Vis absorption spectra of **Fe-TMPP** dispersed in aqueous solution for 0−3 days.



**Figure S9.** The DLS results of **Fe-TMPP** in PBS (0.1x) for 0 (a), 12 (b), and 24 hours (c).




**Figure S10.** The zeta potential results of **Fe-TMPP** in PBS (0.1x) for 0 (a), 12 (b) and 24 hours (c).



**Figure S11.** A comparison of the PXRD spectra of **Fe-TMPP** and its lyophilized samples after sonication and kept in different amounts of water for 24 h.




**Figure S12.** TEM image of **TMPP-F127**.



**Figure S13.** UV-Vis absorption spectra of DPBF (a) and its dispersion in **TMPP-F127** (b) and **Fe-TMPP** (c) aqueous solution with different illumination times. The changes of absorption intensity at 416 nm of DPBF as a function of irradiation time when incubated with **TMPP-F127** and **Fe-TMPP** using blank DPBF as a control (d).



**Figure S14.** A comparison of fluorescence intensity of DCF when treated with **TMPP-F127**, **Fe-TMPP**, and PBS control.



**Figure S15.** A comparison of the HCT-116 (a), HuH-7 (b), and BXPC3 (c) cell viabilities when treated with gradient concentrations of **TMPP-F127** and **Fe-TMPP**. The DLD-1, PC3, and AGS cells viabilities when treated with gradient concentrations of **Fe-TMPP** (d).

**Table S1.** Detailed cell development and drug incubation conditions.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Cell Line** | **Culturing Media** | **Culture Media Supplier** | **Cell Density** | **Incubation Time** |
| 4T1 | RPMI 1640 | Elabscience Crop. | 5 × 103 | 24 h |
| HCT-116 | DMEM | Procell Life Science & Technology Co., Ltd. | 2 × 104 | 24 h |
| HuH-7 | DMEM | Procell Life Science & Technology Co., Ltd. | 2 × 104 | 24 h |
| BXPC3 | RPMI 1640 | Procell Life Science & Technology Co., Ltd. | 2.5 × 103 | 72 h |
| DLD-1 | RPMI 1640 | Procell Life Science & Technology Co., Ltd. | 2 × 103 | 72 h |
| PC3 | RPMI 1640 | Procell Life Science & Technology Co., Ltd. | 2 × 103 | 72 h |
| AGS | Ham's F-12 | Procell Life Science & Technology Co., Ltd. | 2 × 103 | 72 h |